| Ytd | 1.14% | |
| 1y | -30.78% |
| Open | 3.07 | Prev Close | 3.07 | Low | 3.07 | High | 3.25 | Mkt Cap | 56.72M |
| Vol | 22.66K | Avg Vol | 16.47K | EPS | -0.90 | P/E | N/A | Forward P/E | -27.22 |
| Beta | 0.68 | Short Ratio | 0.04 | Inst. Own | 1.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 4.17 | 200-d Avg | 4.04 | 1yr Est | 8.00 |
ATHE News
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on t
Gainers NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 56.7% to $0.16 during Friday's pre
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) has received a consen
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday
Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurode
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a
MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 i
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide
Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:AT
Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnolog
Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, wh
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design
"These data continue to strengthen the evidence that ATH434 has the potential to be the first di
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disea
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the plann
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in
This second Type C Meeting builds on Alterity's recent regulatory interactions with the FDA and
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (AS
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report)
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biot
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidanc
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after
On Wednesday, 479 stocks made new 52-week lows.
Monday saw 196 companies set new 52-week lows.